AFT Pharmaceuticals News
4 FOLLOWERS
AFT Pharmaceuticals' vision is to develop innovative products that help people. They fill in the gaps in the market with innovative products that can provide positive health outcomes for those who need them. The company keeps its readers posted on its activities, plans, yearly analysis, medical research, and more.
AFT Pharmaceuticals News
2w ago
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an Agreement with Hikma Pharmaceuticals USA (“Hikma”) to distribute its patented1 COMBOGESIC® Tablets, a fixed dose combination (FDC) (acetaminophen and ibuprofen), non-opioid analgesia in a single tablet for adult pain management to select markets in the United States, the largest pharma market in the world.2 The Agreement ..read more
AFT Pharmaceuticals News
4M ago
AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring ..read more
AFT Pharmaceuticals News
6M ago
AFT Pharmaceuticals provides an update on recent progress it has made in international markets ..read more
AFT Pharmaceuticals News
7M ago
AFT Pharmaceuticals today announces an update to guidance for the financial year to the end of March 2024 (FY24 ..read more
AFT Pharmaceuticals News
7M ago
AFT Pharmaceuticals announces Maxigesic IV®, the patented intravenous form of its family of pain relief medicines, has today been launched in the US by its licensee Hikma Pharmaceuticals ..read more
AFT Pharmaceuticals News
8M ago
As the new year commences, AFT Pharmaceuticals is looking forward to building upon the significant progress made during 2023. Last year we moved on from the uncertainties of the COVID-19 pandemic and we are pleased with the progress we made, especially in our international markets ..read more
AFT Pharmaceuticals News
8M ago
AFT Pharmaceuticals announces it has entered into a further partnership with one of its long-standing research and development partners, Belgium’s Hyloris Pharmaceuticals to develop a novel treatment for the management of the skin condition Vulvar Lichen Sclerosus (VLS) where there is limited availability of approved treatments ..read more
AFT Pharmaceuticals News
8M ago
AFT Pharmaceuticals today announces that it has entered into a partnership with one of its research and development partners, Belgium’s Hyloris Pharmaceuticals to develop a novel locally acting product for the treatment of Burning Mouth Syndrome (BMS ..read more
AFT Pharmaceuticals News
10M ago
FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023 ..read more
AFT Pharmaceuticals News
11M ago
AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023 ..read more